The present invention relates to a novel process for purifying bacterial polysaccharide at room temperature. It is an efficient and scalable process for removing impurities from Neisseria meningitidis serogroup A (Men-A) polysaccharide which is capable of being used as such in a derivatized form or linked to other m...

The present invention relates to novel polysaccharide-protein conjugates and process to obtain the same. More particularly, the present invention relates to polysaccharide – protein conjugates produced using carbamate chemistry capable of being used in production of monovalent vaccine or multivalent combination vacc...

The present invention relates to a thermostable freeze dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses multivalent thermostable liquid, powder or cake based rotavirus vaccine formulation prepared using the freeze drying process, such that t...

Abstract Polysaccharide – Protein Conjugates With Enhanced Immunogenicity And Rapid High Yielding Process Thereof The present invention relates to polysaccharide – protein conjugates with enhanced immunogenicity displaying significantly high antibody titres. The carrier protein is obtained from group of gram p...

The present invention relates to an improved process of conjugation to obtain synthetic oligosaccharide – protein (OS-PR) conjugates. The process of synthetic OS-PR conjugation is a rapid process providing oligosaccharide – protein conjugates which are highly immunogenic and elicit specific and homogenous immune re...

The present invention relates to a rapid process for producing and purifying Haemophilus influenzae type b polyribosyl ribitol phosphate (Hib-PRP) polysaccharides which meets the WHO specifications. The process yeilds Hib-PRP polysaccharides capable of being used as such, or of being derivatized or linked to other m...

The present invention relates to polysaccharide – protein conjugates with enhanced immunogenicity displaying significantly high antibody titres. The carrier protein is obtained from group of gram positive bacteria, polysaccharide fragment is obtained from group of gram negative bacteria, preferably from Haemophilus ...

The present invention relates to synthesis of novel compound of Haemophilus influenzae type b (Hib) oligosaccharides which meet the expected physico-chemical quality standards for the purity and its use as a candidate for development of conjugate vaccine against Hib infections. The present invention also provides a ...

PROCESS FOR FORMULATING ACID STABILIZED ORAL BACTERIAL VACCINE The present invention relates to a process for formulating acid stabilized oral bacterial vaccine, more particularly a combination of whole cell inactivated bacteria and acid stabilized rCTB (recombinant cholera toxin B) resulting in synergistic pro...

The present invention relates to an improved thermostable spray dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses thermostable liquid, powder or granule-based rotavirus vaccine prepared using the spray drying process, such that the said vacci...

The present invention relates 5 to novel oligomers of Neisseria meningitidis serogroup Y capsular polysaccharide repeating unit (Men-Y oligomers) and process for synthesizing novel Men- Y oligomers. In particular, the present invention relates to the chemical synthesis of the tetramer of Men- Y capsular 10 polysacc...

The present invention is related to novel polysaccharide - protein conjugate vaccine formulation comprising of at least one of Neisseria meningitidis serogroup A, C, Y, W or X synthetic oligosaccharides (Men A, C, Y, W, X), each said oligosaccharide (OS) being conjugated separately to carrier protein., either none o...

The present invention relates to a culture media composition, feed composition and fermentation conditions for production of Neisseria meningitidis polysaccharides. The N. meningitidis polysaccharides of the present invention are capable of being used in the production of economical polysaccharide protein conjugate ...

Novel multivalent polysaccharide – protein conjugate vaccine formulation. The formulation is liquid or lyophilized or a Liquid-Lyo combination pentavalent formulation of Neisseria meningitidis serogroup A, C, Y, W and X capsular polysaccharides (Men A, C, Y, W, X), each said polysaccharide being conjugated separate...

The present invention discloses a rapid high yielding purification process for Neisseria meningitidis serogroup X capsular polysaccharide. The capsular polysaccharide of present invention is capable of being used in the production of economical monovalent capsular polysaccharide or polysaccharide protein conjugate v...

The present invention relates to novel synthetic Neisseria meningitidis Serogroup A (hereinafter MenA) capsular polysaccharide repeating unit oligomer and a process for synthesizing said synthetic MenA capsular polysaccharide repeating unit oligomer. More specifically, the present invention relates to the chemical s...

The present invention particularly relates to culture media composition, feed composition, and fermentation conditions for production of Neisseria meningitidis polysaccharides. The present invention describes a rapid, industrially scalable, cost effective process for the production of Neisseria meningitidis. The N. ...

The present invention discloses frangible seal pouch for integrated reconstitution and administration of medicament. It comprises of pouch and spout of predetermined optimal dimensions to facilitate the optimal administration, storing, packaging and transportation. The pouch comprises of at least two chambers of whi...

The present invention relates to a novel process for purification of bacterial polysaccharide specifically the polysaccharides of Neisseria meningitidis serogroup C, W and Y. It is an efficient process for eliminating impurities from Neisseria meningitidis serogroup C (Men C), W (Men W) and Y (Men Y) polysaccharides...

The present invention relates to a novel polysaccharide - protein conjugate vaccine composition and formulation obtained through optimized fermentation process. The formulation is liquid or lyophilized or liquid-lyo tetravalent formulation of Neisseria meningitidis serogroup A, C, Y and W capsular polysaccharides (M...

The present invention relates to rapid purification of Neisseria meningitidis serogroup W and serogroup Y polysaccharides. The N. meningitidis polysaccharides of the present invention are capable of being used in the production of economical polysaccharide protein conjugate vaccine(s) against meningococcal infection...

The present invention relates to a novel vaccine formulation for Enterotoxigenic E. coli (ETEC) and Vibrio cholerae vaccine and a process to prepare Enterotoxigenic E. coli (ETEC) and Vibrio cholerae vaccine. The formulation provides protection against diarrhea caused by Enterotoxigenic Escherichia coli (ETEC) and V...

The present invention relates to novel Shigella vaccine formulation and process to prepare said vaccine formulation. More particularly, the present invention relates to inactivated whole cell Shigella vaccine formulation comprising whole cell inactivated Shigella strain selected from Shigella flexneri 2a, Shigella 3...